Denis Chem Lab [DENISCHEM] vs Aarti Drugs [AARTIDRUGS] Detailed Stock Comparison
Denis Chem Lab
BSE
Loading...
Aarti Drugs
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Denis Chem Lab wins in 9 metrics, Aarti Drugs wins in 7 metrics, with 0 ties. Denis Chem Lab appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Denis Chem Lab | Aarti Drugs | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.91 | 23.77 | Denis Chem Lab |
| Price-to-Book Ratio | N/A | 3.28 | N/A |
| Debt-to-Equity Ratio | 0.01 | 44.92 | Denis Chem Lab |
| PEG Ratio | N/A | -21.01 | N/A |
| EV/EBITDA | 6.95 | 17.16 | Denis Chem Lab |
| Profit Margin (TTM) | 44.74% | 7.80% | Denis Chem Lab |
| Operating Margin (TTM) | 6.71% | 10.11% | Aarti Drugs |
| EBITDA Margin (TTM) | 6.71% | 10.11% | Aarti Drugs |
| Return on Equity | 9.49% | 12.28% | Aarti Drugs |
| Return on Assets (TTM) | 7.19% | 6.53% | Denis Chem Lab |
| Free Cash Flow (TTM) | $44.64M | $674.20M | Aarti Drugs |
| Dividend Yield | 2.46% | 0.22% | Denis Chem Lab |
| 1-Year Return | -49.24% | -1.73% | Aarti Drugs |
| Price-to-Sales Ratio (TTM) | 0.74 | 1.85 | Denis Chem Lab |
| Enterprise Value | $1.28B | $50.76B | Aarti Drugs |
| EV/Revenue Ratio | 0.74 | 2.10 | Denis Chem Lab |
| Gross Profit Margin (TTM) | 45.03% | 36.77% | Denis Chem Lab |
| Revenue per Share (TTM) | N/A | $265 | N/A |
| Earnings per Share (Diluted) | $5.82 | $20.66 | Aarti Drugs |
| Beta (Stock Volatility) | N/A | 0.21 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Denis Chem Lab vs Aarti Drugs Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Denis Chem Lab | -1.19% | -7.53% | -8.32% | -3.12% | -35.72% | -46.48% |
| Aarti Drugs | -2.85% | 0.47% | 3.52% | 17.71% | 21.40% | 7.96% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Denis Chem Lab | -49.24% | 39.27% | 94.89% | 206.22% | 296.28% | 296.28% |
| Aarti Drugs | -1.73% | 18.09% | -4.28% | 213.79% | 2,742.22% | 2,387.47% |
Performance & Financial Health Analysis: Denis Chem Lab vs Aarti Drugs
| Metric | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.28B | ₹44.83B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,855 | 276,955 |
| 90 Day Avg. Volume | 6,748 | 692,287 |
| Last Close | ₹91.50 | ₹491.75 |
| 52 Week Range | ₹87.99 - ₹193.00 | ₹312.00 - ₹635.00 |
| % from 52W High | -52.59% | -22.56% |
| All-Time High | ₹232.90 (Jun 17, 2024) | ₹1,026.95 (Oct 05, 2020) |
| % from All-Time High | -60.71% | -52.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.03% | 0.06% |
| Quarterly Earnings Growth | 0.04% | 0.62% |
| Financial Health | ||
| Profit Margin (TTM) | 0.45% | 0.08% |
| Operating Margin (TTM) | 0.07% | 0.10% |
| Return on Equity (TTM) | 0.09% | 0.12% |
| Debt to Equity (MRQ) | 0.01 | 44.92 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | N/A | ₹149.84 |
| Cash per Share (MRQ) | N/A | ₹2.48 |
| Operating Cash Flow (TTM) | ₹105.01M | ₹2.83B |
| Levered Free Cash Flow (TTM) | ₹80.76M | ₹1.68B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.46% | 0.22% |
| Last 12-Month Dividend | ₹2.50 | ₹1.00 |
Valuation & Enterprise Metrics Analysis: Denis Chem Lab vs Aarti Drugs
| Metric | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.91 | 23.77 |
| Forward P/E | N/A | 15.13 |
| PEG Ratio | N/A | -21.01 |
| Price to Sales (TTM) | 0.74 | 1.85 |
| Price to Book (MRQ) | N/A | 3.28 |
| Market Capitalization | ||
| Market Capitalization | ₹1.28B | ₹44.83B |
| Enterprise Value | ₹1.28B | ₹50.76B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.74 | 2.10 |
| Enterprise to EBITDA | 6.95 | 17.16 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.21 |
| Book Value per Share (MRQ) | N/A | ₹149.84 |
Financial Statements Comparison: Denis Chem Lab vs Aarti Drugs
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Revenue/Sales | ₹413.83M | ₹6.77B |
| Cost of Goods Sold | ₹227.48M | ₹4.37B |
| Gross Profit | ₹186.36M | ₹2.40B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹3.24M | ₹784.50M |
| EBITDA | ₹32.28M | ₹951.90M |
| Pre-Tax Income | ₹12.66M | ₹711.50M |
| Income Tax | ₹5.59M | ₹83.80M |
| Net Income (Profit) | ₹7.08M | ₹627.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Cash & Equivalents | ₹8.50M | ₹45.80M |
| Total Current Assets | ₹706.45M | ₹13.38B |
| Total Current Liabilities | ₹261.73M | ₹8.37B |
| Long-Term Debt | ₹4.53M | ₹2.86B |
| Total Shareholders Equity | ₹851.04M | ₹13.69B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹387.18M | ₹8.59B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,855 | 276,955 |
| Average Daily Volume (90 Day) | 6,748 | 692,287 |
| Shares Outstanding | 13.88M | 91.27M |
| Float Shares | N/A | 35.46M |
| % Held by Insiders | 0.80% | 0.61% |
| % Held by Institutions | 0.00% | 0.11% |
Dividend Analysis & Yield Comparison: Denis Chem Lab vs Aarti Drugs
| Metric | DENISCHEM | AARTIDRUGS |
|---|---|---|
| Last 12-Month Dividend | ₹2.50 | ₹1.00 |
| Last 12-Month Dividend Yield | 2.46% | 0.22% |
| 3-Year Avg Annual Dividend | ₹3.17 | ₹1.00 |
| 3-Year Avg Dividend Yield | 1.78% | 0.23% |
| 3-Year Total Dividends | ₹9.50 | ₹3.00 |
| Ex-Dividend Date | Sep 19, 2024 | Feb 04, 2025 |